Akathisia can be one of the most distressing medication-related movement problems because it is felt from the inside as much as it is seen from the outside. A person may look restless, tense, irritable, or unable to sit still, but the deeper problem is often an intense inner unease that feels difficult to describe and hard to escape.
Because akathisia is commonly linked to antipsychotic medicines and can also occur with some other medications, good care depends on recognizing it early, taking the person’s distress seriously, and adjusting treatment safely. It should not be dismissed as “just anxiety,” “noncompliance,” or worsening mental illness without first considering whether medication may be driving the restlessness.
Table of Contents
- What Akathisia Feels Like
- Causes and Risk Factors
- Diagnosis and Urgent Warning Signs
- First Treatment Steps
- Akathisia Medication Options
- Therapy, Support, and Daily Coping
- Recovery Timeline and Follow-Up
What Akathisia Feels Like
Akathisia is best understood as a medication-related state of inner restlessness, usually with a powerful urge to move. The person may pace, rock, shift weight, cross and uncross the legs, or feel unable to remain seated, but some people mainly feel the inner distress without obvious movement.
People often describe akathisia in phrases such as:
- “I feel like I want to crawl out of my skin.”
- “I cannot settle, even when I am exhausted.”
- “My body feels driven to move.”
- “I feel anxious, but it is not normal anxiety.”
- “Sitting still feels unbearable.”
That last distinction matters. Anxiety can make someone restless, but akathisia often has a more physical, driven quality. It may appear soon after starting a medicine, raising a dose, restarting a medicine after a break, or sometimes reducing or stopping a medication. When it follows a medication change, the timeline is an important clue.
Akathisia can be mild, moderate, or severe. Mild akathisia may look like fidgeting, leg bouncing, or frequent position changes. Moderate akathisia can interfere with meals, conversations, sleep, work, or appointments. Severe akathisia can feel intolerable and may cause panic, agitation, impulsive behavior, or thoughts of self-harm. Because of that, clinicians should ask directly about distress and safety rather than judging only by how much movement is visible.
Akathisia is also easy to misread. It may be mistaken for worsening psychosis, mania, agitation, attention problems, withdrawal, insomnia, restless legs syndrome, or severe anxiety. In psychiatric settings, this misreading can be especially risky because increasing the dose of the medication that caused the problem may worsen the restlessness. A careful history is often more useful than a quick visual impression.
It can also overlap with other medication-related movement problems. Tardive dyskinesia, for example, usually involves involuntary movements such as lip smacking, tongue movements, facial movements, or choreiform movements, while akathisia is centered on inner restlessness and the urge to move. Some people have more than one movement side effect at the same time, which is one reason medication review should be done by a clinician familiar with psychiatric and neurologic side effects. For more context on related medication-induced movement problems, see tardive dyskinesia management.
The most important practical point is simple: new, intense restlessness after a medication change deserves prompt medical attention. The person should not be blamed for being difficult, impatient, or unwilling to cooperate. Akathisia is a real and treatable condition.
Causes and Risk Factors
Akathisia is most often associated with dopamine-blocking medications, especially antipsychotics. It can occur with older first-generation antipsychotics and with newer second-generation antipsychotics, although risk varies by drug, dose, speed of dose increase, and individual vulnerability.
Common medication contexts include:
- Starting an antipsychotic for psychosis, bipolar disorder, severe agitation, depression augmentation, nausea, or another indication.
- Raising the dose quickly.
- Using higher doses than needed.
- Taking more than one dopamine-blocking medication.
- Restarting medication after time off.
- Reducing a medication used to manage other extrapyramidal side effects.
- Using some anti-nausea medicines that block dopamine, such as metoclopramide or prochlorperazine.
- Less commonly, starting or changing certain antidepressants or other psychiatric medicines.
Not everyone who takes these medicines develops akathisia. Risk is shaped by the medication, the dose, the rate of change, and the person’s medical history. Higher-potency antipsychotics, rapid titration, and antipsychotic polypharmacy can raise risk. Younger people, people early in antipsychotic treatment, and people with a past episode of akathisia may be more vulnerable.
The condition can also appear in different time patterns. Acute akathisia usually develops within days to weeks of starting or increasing a medication. Chronic akathisia persists for longer, often beyond several months. Withdrawal akathisia may appear after reducing or stopping a medication. Tardive akathisia is a later-onset form that can emerge after longer exposure and may persist even after medication changes. A separate discussion of tardive akathisia can be helpful when symptoms are delayed, prolonged, or difficult to connect to a recent change.
Akathisia is not caused by poor willpower, weak coping skills, or simply “being anxious.” Psychological distress can make it feel worse, but the underlying problem is usually medication-related neurochemical disruption. The exact mechanism is not fully settled, but dopamine pathways, serotonin-dopamine balance, and other neurotransmitter systems are thought to be involved.
Because akathisia often develops in people taking medications for serious mental health conditions, treatment decisions can be delicate. Stopping the suspected medication suddenly may relieve one problem but destabilize another. For example, someone taking an antipsychotic for mania, psychosis, severe depression, or agitation may need dose changes, a switch, or add-on treatment rather than abrupt discontinuation. These decisions should be made with the prescribing clinician whenever possible.
A practical risk-reduction approach is to start medicines carefully, increase doses gradually when clinically appropriate, avoid unnecessary medication overlap, and ask about inner restlessness at each follow-up. People who have had akathisia before should tell every prescriber, including emergency clinicians, primary care doctors, psychiatrists, neurologists, and clinicians prescribing anti-nausea medication.
Diagnosis and Urgent Warning Signs
Akathisia is diagnosed mainly through history, symptom description, observed movement, and medication timing. There is no single blood test or scan that confirms it, so the clinician’s task is to connect the person’s experience with recent medication exposure while ruling out look-alike conditions.
A good evaluation usually includes:
- A full medication list, including recent starts, stops, dose increases, missed doses, injections, anti-nausea drugs, sleep medicines, and supplements.
- A timeline of when restlessness began and whether it worsened after medication changes.
- Questions about subjective distress, not only visible pacing or fidgeting.
- Observation of sitting, standing, walking, leg movement, posture changes, and ability to remain still.
- Screening for anxiety, mania, psychosis, withdrawal, substance use, restless legs symptoms, insomnia, and neurologic conditions.
- Assessment of depression, impulsivity, suicidal thoughts, and ability to stay safe.
Clinicians may use the Barnes Akathisia Rating Scale, often called BARS, to assess objective movement, subjective awareness of restlessness, distress, and overall severity. A rating scale does not replace clinical judgment, but it helps track whether symptoms are improving after a dose change, medication switch, or add-on treatment.
The main diagnostic challenge is that akathisia can look like psychiatric agitation. In someone with psychosis, for example, pacing and distress may be interpreted as worsening illness. In someone with anxiety, it may be labeled panic or agitation. In someone with insomnia, it may be viewed as sleep frustration. These can coexist with akathisia, but the key question is whether the restlessness is new, physically driven, and temporally related to medication.
Some warning signs require urgent same-day medical contact or emergency evaluation:
- New suicidal thoughts, self-harm urges, or feeling unable to stay safe.
- Violent impulses or fear of losing control.
- Severe restlessness with inability to sleep, eat, sit, or function.
- Confusion, fever, severe muscle stiffness, unstable blood pressure, or a racing heart.
- Severe agitation after a medication injection or recent dose increase.
- New restlessness with chest pain, fainting, shortness of breath, or severe weakness.
- Signs of dehydration, exhaustion, or inability to care for basic needs.
Akathisia itself is not the same as neuroleptic malignant syndrome, serotonin syndrome, mania, or delirium, but severe medication reactions can overlap in confusing ways. Fever, rigidity, confusion, and unstable vital signs are not typical uncomplicated akathisia and need urgent medical assessment. For a related medication emergency, see neuroleptic malignant syndrome.
The safest rule is to treat severe akathisia as clinically important, not as a nuisance side effect. Even when the evidence linking akathisia directly to suicidal behavior is mixed, the distress can be extreme enough that proactive safety assessment is essential.
First Treatment Steps
The first step in treating akathisia is to identify the likely trigger and decide whether the medication plan can be changed safely. The most effective intervention is often not adding another drug, but reducing exposure to the medication that caused the restlessness.
Treatment usually starts with a prescriber reviewing several questions:
- Did symptoms begin after starting, increasing, restarting, or injecting a medication?
- Is the current dose higher than needed?
- Is the dose being increased too quickly?
- Are multiple dopamine-blocking medicines being used?
- Can the medicine be reduced, paused, or switched without destabilizing the underlying condition?
- Is the person at immediate safety risk?
When clinically feasible, the prescriber may lower the dose of the suspected medication. This can reduce akathisia while preserving treatment benefit. If symptoms remain significant, switching to a medication with a lower akathisia risk may be considered. For antipsychotic-induced akathisia, clinicians may consider changing to another antipsychotic based on the person’s diagnosis, past response, side-effect history, relapse risk, metabolic risk, sedation risk, and personal preferences.
Abruptly stopping medication without medical guidance is usually not the safest choice. Sudden discontinuation can lead to relapse, withdrawal symptoms, rebound insomnia, anxiety, agitation, or return of psychosis or mania. The exception is a medical emergency, where urgent care may stop or change medication quickly under supervision.
Medication simplification can also help. If someone is taking more than one antipsychotic, or taking an antipsychotic plus a dopamine-blocking anti-nausea medicine, reducing overlap may lower the total burden. A pharmacist can be valuable here because dopamine-blocking effects may come from medicines prescribed by different clinicians.
The early treatment plan should also include close follow-up. Akathisia can change quickly, especially after a dose adjustment. A follow-up within days may be needed for moderate or severe symptoms. The person and family should know whom to call if symptoms worsen, if sleep collapses, or if safety concerns emerge.
It is also important to avoid a common trap: assuming restlessness means the original psychiatric condition is worsening. Sometimes the correct response is not more antipsychotic medication but less of the offending drug, a slower titration, a different medication, or an add-on treatment specifically for akathisia.
For people who feel frightened by medication side effects, a balanced decision process can reduce the urge to stop everything suddenly. A practical discussion of medication side-effect fears may help people prepare better questions for their prescriber and make safer treatment decisions.
Akathisia Medication Options
Medication for akathisia is usually considered when dose reduction or switching is not enough, not possible, or not safe to do quickly. The choice depends on the cause, severity, medical history, blood pressure, heart rate, sleep, anxiety, substance-use risk, and other side effects.
There is no perfect medication for akathisia. Evidence for add-on treatments is limited, and studies are often small. Still, several options are used in clinical practice.
| Option | How it may help | Important cautions |
|---|---|---|
| Reduce the offending medication | Lowers the medication exposure driving restlessness | May risk return of psychosis, mania, nausea, or another treated condition if done too quickly |
| Switch medication | May preserve treatment while reducing akathisia risk | Requires careful cross-taper planning and monitoring |
| Beta-blocker such as propranolol | May reduce physical restlessness and inner agitation | Can lower heart rate or blood pressure; may not be suitable with asthma, some heart conditions, or certain medications |
| 5-HT2A antagonist options such as mirtazapine | May help some cases, especially when sleep or appetite also need support | Can cause sedation, weight gain, or other side effects; not appropriate for everyone |
| Benzodiazepine medication | May provide short-term relief from severe distress and agitation | Risk of sedation, falls, dependence, tolerance, and interaction with alcohol or opioids |
| Anticholinergic medication | May help if akathisia occurs with parkinsonism or other extrapyramidal symptoms | Can worsen constipation, urinary retention, dry mouth, confusion, memory problems, or glaucoma risk |
Propranolol has long been used for antipsychotic-induced akathisia and is often considered when there are no contraindications. It may be started at a low dose and adjusted based on symptoms, pulse, blood pressure, and tolerability. It is not a good fit for everyone, especially people with certain heart rhythm problems, low blood pressure, some types of asthma, or significant dizziness.
Mirtazapine is another option used in some cases, especially at lower doses. It may be considered when sleep disruption, appetite loss, or depressive symptoms are also present, but it can cause sedation and weight gain. It should not be added casually or combined with other sedating medications without a clear plan.
Benzodiazepines may help short-term, particularly when distress is severe, but they are not ideal as a long-term solution for many people. They can impair driving, increase fall risk, worsen sleep-disordered breathing, and cause dependence. They require extra caution in older adults and in anyone using alcohol, opioids, or other sedating substances.
Anticholinergic medicines such as benztropine are often more useful for medication-induced parkinsonism or dystonia than for pure akathisia. They may be considered when symptoms overlap, but they can cause troublesome side effects, particularly in older adults or people with cognitive problems.
Vitamin B6 has been studied as an add-on option in some trials, but it should not be self-prescribed at high doses. Excessive vitamin B6 can cause nerve problems, and supplement quality varies. If considered, it should be discussed with a clinician who can weigh dose, duration, medication interactions, and medical history.
The best medication plan is individualized. A person with low blood pressure may not tolerate propranolol. A person with severe insomnia may benefit from a sedating option but may be harmed by next-day grogginess. A person with substance-use risk may need to avoid benzodiazepines. A person with psychosis relapse risk may need a careful antipsychotic switch rather than abrupt reduction.
Therapy, Support, and Daily Coping
Therapy and coping strategies do not cure medication-induced akathisia by themselves, but they can reduce fear, improve communication, and help the person stay safe while medical treatment is adjusted. Support is especially important because akathisia can feel frightening, isolating, and hard to explain.
The first supportive step is validation. Family members, clinicians, and caregivers should avoid saying “calm down,” “stop pacing,” or “you’re just anxious.” A better response is: “This looks very uncomfortable. Let’s write down when it started and call your prescriber.” That kind of response reduces shame and helps move the situation toward care.
Useful daily supports include:
- Keeping a symptom log with medication times, dose changes, restlessness level, sleep, meals, and triggers.
- Rating symptoms at the same times each day to show whether treatment changes are helping.
- Reducing caffeine, stimulants, and recreational substances that can intensify agitation.
- Using low-stimulation environments when symptoms peak.
- Taking safe, brief walks if movement relieves distress.
- Avoiding long seated obligations during severe episodes when possible.
- Asking a trusted person to attend appointments and help describe symptoms.
- Creating a safety plan for nights, weekends, or times when the prescriber is unavailable.
Psychotherapy can help with the secondary emotional impact: fear of medication, loss of trust, embarrassment, panic about symptoms, or trauma from a severe episode. Cognitive behavioral strategies may help a person identify catastrophic thoughts and communicate more clearly, but therapy should not be used to imply that akathisia is purely psychological. The medical cause still needs attention.
When akathisia occurs in someone being treated for psychosis, bipolar disorder, severe depression, or another serious condition, family or caregiver education can make treatment safer. Supporters can watch for changes in sleep, pacing, irritability, medication adherence, and suicidal statements. They can also help prevent sudden medication stopping by encouraging urgent prescriber contact instead.
Work and school accommodations may be needed temporarily. Sitting through long meetings, classes, exams, therapy groups, or waiting rooms may be difficult. Short breaks, permission to stand, reduced stimulation, remote visits, or shorter appointments can help until symptoms improve.
Sleep deserves special attention. Akathisia can destroy sleep, and sleep loss can worsen distress, impulsivity, and psychiatric symptoms. The plan may include medication adjustments, temporary sleep support, light exposure in the morning, avoiding late caffeine, and reducing nighttime stimulation. If the person cannot sleep for more than a night or two because of severe restlessness, that should be treated as clinically urgent.
Support also means watching language. A person with akathisia may say, “I can’t take this anymore.” That may describe distress, but it can also signal risk. Ask directly and calmly whether they are thinking about harming themselves. Direct questions do not create suicidal thoughts; they help uncover risk that needs immediate care.
Recovery Timeline and Follow-Up
Recovery from akathisia depends on how quickly it is recognized, the medication involved, the treatment plan, and whether symptoms are acute, chronic, withdrawal-related, or tardive. Many acute cases improve after the offending medication is reduced, stopped, or switched, but recovery is not always immediate.
Some people feel better within days of a successful medication adjustment. Others improve gradually over several weeks. Chronic or tardive akathisia can last longer and may need specialist management. When an antipsychotic injection is involved, symptoms may take longer to settle because the medication remains active in the body for an extended period.
Follow-up should focus on both symptom relief and stability of the underlying condition. A plan that removes akathisia but causes relapse is not a good plan. Likewise, a plan that controls psychosis or mood symptoms while leaving the person in unbearable restlessness is not acceptable. Good care aims for both psychiatric stability and tolerable movement side effects.
A follow-up visit should review:
- Current restlessness compared with baseline.
- Sleep, appetite, pacing, ability to sit, and ability to function.
- Suicidal thoughts, impulsivity, anger, or fear of losing control.
- Medication adherence and missed doses.
- Blood pressure, pulse, sedation, dizziness, or falls if add-on medicines are used.
- Whether the treatment target is still appropriate.
- Whether a lower-risk medication strategy is possible.
People who have experienced akathisia should keep a written record of the suspected medication, dose, timing, symptoms, and what helped. This is useful in emergency departments, psychiatric admissions, primary care visits, and future prescribing decisions. It may prevent the same medication pattern from being repeated.
Recovery can also involve rebuilding trust. A severe akathisia episode can make people afraid of all psychiatric medications. That fear is understandable, but it can be addressed with slower titration, shared decision-making, careful side-effect monitoring, and a clear plan for what to do if symptoms return. People should be encouraged to report early restlessness rather than waiting until it becomes severe.
Relapse prevention is practical. Prescribers can use the lowest effective dose, avoid unnecessary polypharmacy, increase doses gradually when clinically possible, schedule early follow-up after medication changes, and ask specifically about inner restlessness. Patients and families can report symptoms early, avoid sudden medication changes unless directed, and seek urgent help if distress escalates.
Akathisia is treatable, but it requires respect for the person’s lived experience. The visible pacing is only part of the problem. The inner distress is often the part that needs the most careful listening.
References
- Akathisia 2023 (Review)
- Comparative Efficacy and Acceptability of Treatment Strategies for Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-analysis 2024 (Systematic Review and Network Meta-analysis)
- How to manage antipsychotic-induced akathisia 2021 (Review)
- The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review 2021 (Systematic Review)
- Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists 2020 (Review)
- The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia 2020 (Guideline)
Disclaimer
This content is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Akathisia can be severe and may require prompt medication review; seek urgent help if restlessness is intense, safety feels uncertain, or suicidal thoughts appear.
Please share this article on Facebook, X (formerly Twitter), or your preferred platform to help others recognize akathisia early and seek appropriate care.
